Journal article
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Abstract
PURPOSE: The relevance of the MET/hepatocyte growth factor pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease.
PATIENTS AND METHODS: PHL86/NCI#9322 (NCT01935934) is a single arm study that evaluated cabozantinib (60 mg once daily) in women with endometrial cancer with progression after chemotherapy. Coprimary endpoints were response rate and 12-week progression-free-survival (PFS). …
Authors
Dhani NC; Hirte HW; Wang L; Burnier JV; Jain A; Butler MO; Welch S; Fleming GF; Hurteau J; Matsuo K
Journal
Clinical Cancer Research, Vol. 26, No. 11, pp. 2477–2486
Publisher
American Association for Cancer Research (AACR)
Publication Date
June 1, 2020
DOI
10.1158/1078-0432.ccr-19-2576
ISSN
1078-0432